Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.73 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.55 |
| ▸ | TET3 | O43151 | 1/20 | 0.52 |
| ▸ | VEGFA | P15692 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.52 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.52 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070970 | 0.86 | EGLN1 (0.57) | EGLN1BBOX1FTOEGLN3VEGFA | |
| SCHEMBL14649383 | 0.84 | EGLN1 (0.73) | EGLN1BBOX1FTOEGLN3VEGFA | |
| SCHEMBL523711 | 0.82 | EGLN1 (0.70) | EGLN1BBOX1FTOEGLN3TET3 | |
| SCHEMBL30274432 | 0.82 | EGLN1 (0.70) | EGLN1BBOX1FTOEGLN3TET3 | |
| SCHEMBL4070258 | 0.81 | EGLN1 (0.68) | EGLN1BBOX1FTOEGLN3THRA | |
| SCHEMBL4077943 | 0.80 | EGLN1 (0.50) | EGLN1BBOX1FTO | |
| SCHEMBL31501044 | 0.80 | EGLN1 (0.68) | EGLN1BBOX1FTOEGLN3EGLN2 | |
| SCHEMBL821293 | 0.80 | EGLN1 (0.68) | EGLN1BBOX1FTOEGLN3EGLN2 | |
| SCHEMBL1219109 | 0.79 | EGLN1 (0.65) | EGLN1BBOX1FTOASPHKDM8 | |
| SCHEMBL2926639 | 0.79 | EGLN1 (0.53) | EGLN1BBOX1FTOEGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-20060258702-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. (US) | 2006-11-16 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1538160-A1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN, INC. (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | claimed |
| EP-0911340-A2 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | disclosed |
| EP-0911340-A2 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885BBOX1 629/4885FTO 1391/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885BBOX1 300/4885FTO 4661/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 24/4885BBOX1 418/4885FTO 1546/4885 |
| US-20060258702-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | EGLN1 7/4885BBOX1 827/4885FTO 3968/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 21/4885BBOX1 435/4885FTO 1235/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 24/4885BBOX1 418/4885FTO 1546/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885BBOX1 2822/4885FTO 2804/4885 |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885BBOX1 1073/4885FTO 2629/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885BBOX1 1285/4885FTO 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.